Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort

J Am Acad Dermatol. 2024 Mar 29:S0190-9622(24)00540-1. doi: 10.1016/j.jaad.2024.03.029. Online ahead of print.

¹ Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona; Department of Oncology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China.
² Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
³ Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
⁴ Division of Thoracic Surgery, Mayo Clinic, Scottsdale, Arizona.
⁵ Department of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona.
⁶ Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona.
⁷ Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
⁸ Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona. Electronic address: Yang.Ping@mayo.edu.

No abstract available

Keywords: dermatologic toxicity; immunotherapy; lung cancer; survival; targeted therapy.